[go: up one dir, main page]

MX2015012610A - Pacritinib deuterizado. - Google Patents

Pacritinib deuterizado.

Info

Publication number
MX2015012610A
MX2015012610A MX2015012610A MX2015012610A MX2015012610A MX 2015012610 A MX2015012610 A MX 2015012610A MX 2015012610 A MX2015012610 A MX 2015012610A MX 2015012610 A MX2015012610 A MX 2015012610A MX 2015012610 A MX2015012610 A MX 2015012610A
Authority
MX
Mexico
Prior art keywords
pacritinib
deuterated
formula
compound
pharmaceutically acceptable
Prior art date
Application number
MX2015012610A
Other languages
English (en)
Inventor
Scott L Harbeson
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of MX2015012610A publication Critical patent/MX2015012610A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención, en una modalidad, proporciona un compuesto de la Fórmula I; (ver Fórmula) o una sal farmacéuticamente aceptable del mismo, en donde las variables mostradas en la Fórmula I son como se definen en la especificación.
MX2015012610A 2013-03-14 2014-03-12 Pacritinib deuterizado. MX2015012610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785727P 2013-03-14 2013-03-14
PCT/US2014/023968 WO2014159511A1 (en) 2013-03-14 2014-03-12 Deuterated pacritinib

Publications (1)

Publication Number Publication Date
MX2015012610A true MX2015012610A (es) 2016-02-17

Family

ID=51625183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012610A MX2015012610A (es) 2013-03-14 2014-03-12 Pacritinib deuterizado.

Country Status (7)

Country Link
US (1) US20160009732A1 (es)
EP (1) EP2970213A4 (es)
JP (1) JP2016512530A (es)
AU (1) AU2014240478A1 (es)
CA (1) CA2904148A1 (es)
MX (1) MX2015012610A (es)
WO (1) WO2014159511A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105017282B (zh) * 2015-08-28 2017-11-07 苏州明锐医药科技有限公司 帕克替尼的制备方法
KR102582752B1 (ko) 2016-12-13 2023-09-22 프린스턴 드러그 디스커버리 인크 단백질 키나아제 억제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0014022D0 (en) * 2000-06-08 2000-08-02 Novartis Ag Organic compounds
WO2004078682A2 (en) * 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
TWI525096B (zh) * 2005-11-16 2016-03-11 Ｃｔｉ生技製藥有限公司 氧連接之嘧啶衍生物

Also Published As

Publication number Publication date
JP2016512530A (ja) 2016-04-28
EP2970213A4 (en) 2016-09-07
CA2904148A1 (en) 2014-10-02
WO2014159511A1 (en) 2014-10-02
US20160009732A1 (en) 2016-01-14
AU2014240478A1 (en) 2015-09-17
EP2970213A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
MX2015002040A (es) Baricitinib deuterado.
IN2015DN00598A (es)
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
MX2015008829A (es) Momelotinib deuterado.
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MX2015012743A (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
PH12018500903A1 (en) Pyranodipyridine compound
IN2014DN07996A (es)
HK1222848A1 (zh) 用作alk抑制剂的吡咯并三嗪
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
IN2014DN10669A (es)
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
MX2015012610A (es) Pacritinib deuterizado.
MX2016006807A (es) Derivados de imidazol.
EA201690593A1 (ru) Новые соединения мочевины
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями
UA89447U (ru) Соединение 1,1-диэтилкарбокси-2-хлор-2-трифторметилэтилен с потенциальными физиологическими свойствами
UA87254U (ru) Соединение 1,1-диэтилкарбокси-2-метокси-2-трифторметилэтилен с потенциальными физиологическими свойствами
UA91886U (uk) 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол